Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy

Cholangiocarcinoma (CCA) is a rare disease with poor prognosis, and surgery remains the only curative treatment option. However, surgery is inappropriate for the majority of patients with CCA. Conversion therapy may provide opportunities for the surgical treatment of these patients. Herein, we descr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xi, Tang, Hao, Fan, Jun, Wang, Rui, Han, Yunwei, Su, Song, Gan, Yu, Peng, Fangyi, Rao, Mingyue, Zhang, Jianwen, Li, Bo, Yang, Xiaoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816130/
https://www.ncbi.nlm.nih.gov/pubmed/36618353
http://dx.doi.org/10.3389/fimmu.2022.1051130
_version_ 1784864462188052480
author Zhang, Xi
Tang, Hao
Fan, Jun
Wang, Rui
Han, Yunwei
Su, Song
Gan, Yu
Peng, Fangyi
Rao, Mingyue
Zhang, Jianwen
Li, Bo
Yang, Xiaoli
author_facet Zhang, Xi
Tang, Hao
Fan, Jun
Wang, Rui
Han, Yunwei
Su, Song
Gan, Yu
Peng, Fangyi
Rao, Mingyue
Zhang, Jianwen
Li, Bo
Yang, Xiaoli
author_sort Zhang, Xi
collection PubMed
description Cholangiocarcinoma (CCA) is a rare disease with poor prognosis, and surgery remains the only curative treatment option. However, surgery is inappropriate for the majority of patients with CCA. Conversion therapy may provide opportunities for the surgical treatment of these patients. Herein, we describe a patient with intrahepatic CCA who was first treated with albumin-bound paclitaxel, cisplatin, and gemcitabine in combination with camrelizumab. The patient then successfully underwent surgery and achieved pathological complete remission. This report can serve as a reference for clinicians regarding conversion therapy for intrahepatic CCA.
format Online
Article
Text
id pubmed-9816130
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98161302023-01-07 Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy Zhang, Xi Tang, Hao Fan, Jun Wang, Rui Han, Yunwei Su, Song Gan, Yu Peng, Fangyi Rao, Mingyue Zhang, Jianwen Li, Bo Yang, Xiaoli Front Immunol Immunology Cholangiocarcinoma (CCA) is a rare disease with poor prognosis, and surgery remains the only curative treatment option. However, surgery is inappropriate for the majority of patients with CCA. Conversion therapy may provide opportunities for the surgical treatment of these patients. Herein, we describe a patient with intrahepatic CCA who was first treated with albumin-bound paclitaxel, cisplatin, and gemcitabine in combination with camrelizumab. The patient then successfully underwent surgery and achieved pathological complete remission. This report can serve as a reference for clinicians regarding conversion therapy for intrahepatic CCA. Frontiers Media S.A. 2022-12-23 /pmc/articles/PMC9816130/ /pubmed/36618353 http://dx.doi.org/10.3389/fimmu.2022.1051130 Text en Copyright © 2022 Zhang, Tang, Fan, Wang, Han, Su, Gan, Peng, Rao, Zhang, Li and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhang, Xi
Tang, Hao
Fan, Jun
Wang, Rui
Han, Yunwei
Su, Song
Gan, Yu
Peng, Fangyi
Rao, Mingyue
Zhang, Jianwen
Li, Bo
Yang, Xiaoli
Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy
title Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy
title_full Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy
title_fullStr Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy
title_full_unstemmed Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy
title_short Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy
title_sort case report: a report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816130/
https://www.ncbi.nlm.nih.gov/pubmed/36618353
http://dx.doi.org/10.3389/fimmu.2022.1051130
work_keys_str_mv AT zhangxi casereportareportofthecompletepathologicalresponseofintrahepaticcholangiocarcinomaafterconversiontherapy
AT tanghao casereportareportofthecompletepathologicalresponseofintrahepaticcholangiocarcinomaafterconversiontherapy
AT fanjun casereportareportofthecompletepathologicalresponseofintrahepaticcholangiocarcinomaafterconversiontherapy
AT wangrui casereportareportofthecompletepathologicalresponseofintrahepaticcholangiocarcinomaafterconversiontherapy
AT hanyunwei casereportareportofthecompletepathologicalresponseofintrahepaticcholangiocarcinomaafterconversiontherapy
AT susong casereportareportofthecompletepathologicalresponseofintrahepaticcholangiocarcinomaafterconversiontherapy
AT ganyu casereportareportofthecompletepathologicalresponseofintrahepaticcholangiocarcinomaafterconversiontherapy
AT pengfangyi casereportareportofthecompletepathologicalresponseofintrahepaticcholangiocarcinomaafterconversiontherapy
AT raomingyue casereportareportofthecompletepathologicalresponseofintrahepaticcholangiocarcinomaafterconversiontherapy
AT zhangjianwen casereportareportofthecompletepathologicalresponseofintrahepaticcholangiocarcinomaafterconversiontherapy
AT libo casereportareportofthecompletepathologicalresponseofintrahepaticcholangiocarcinomaafterconversiontherapy
AT yangxiaoli casereportareportofthecompletepathologicalresponseofintrahepaticcholangiocarcinomaafterconversiontherapy

Ejemplares similares